Internal Server Error

Bota - About the company

Bota is a series B company based in Lafayette (United States), founded in 2019 by Cheryl Cui. It operates as a Developer of AI-based platform for enzyme and strain engineering. Bota has raised $100M in funding from investors like BASF, CMB International Capital and Matrix Partners China. The company has 69 active competitors, including 20 funded and 14 that have exited. Its top competitors include companies like Senti Bio, CRISPR Therapeutics and ADARx Pharmaceuticals.

Company Details

Developer of AI-based platform for enzyme and strain engineering. This technology is used for producing microbe-based products in industries and also helps in fermentation. The engineered enzymes and strains are developed to tolerate harsh environments, eliminate the accumulation of intermediates, and increase productivity. The company has also developed a fermentation process for producing engineered strains and enzymes.
Website
bota.bio
Social
X
Key Metrics
Founded Year
2019
Location
Lafayette, United States
Stage
Series B
Total Funding
$100M in 2 rounds
Latest Funding Round
Investors
Ranked
Employee Count
45 as on Sep 30, 2026
Similar Companies
Sign up to download Bota's company profile

Bota's funding and investors

Bota has raised a total funding of $100M over 2 rounds. Its first funding round was on Mar 16, 2021. Its latest funding round was a Series B round on Jul 29, 2021 for $*****. 7 investors participated in its latest round. Bota has 11 institutional investors.

Here is the list of recent funding rounds of Bota:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Jul 29, 2021
4514625
Series B
5815403
3627036
4277320
6606033
Mar 16, 2021
7300584
Seed
8485872
8788442
5823480
lockAccess funding benchmarks and valuations. Sign up today!

Bota's founders and board of directors

Founder? Claim Profile
The founders of Bota is Cheryl Cui.
Here are the details of Bota's key team members:

Bota's employee count trend

Bota has 45 employees as of Sep 26. Here is Bota's employee count trend over the years:
Employee count trend for Bota
lockUncover Bota's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Bota's Competitors and alternates

Top competitors of Bota include Senti Bio, CRISPR Therapeutics and ADARx Pharmaceuticals. Here is the list of Top 10 competitors of Bota, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Senti Bio
Senti Bio
2016, San Francisco (United States), Public
Developer of cell and gene therapies for patients living with incurable diseases
$158M
72/100
2nd
Logo for CRISPR Therapeutics
CRISPR Therapeutics
2013, Basel (Switzerland), Public
Developer of solutions for treating human genetic diseases by using genome editing technology
$127M
63/100
3rd
Logo for ADARx Pharmaceuticals
ADARx Pharmaceuticals
2019, San Diego (United States), Public
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts
$353M
61/100
4th
Logo for Geninus
Geninus
2018, Seoul (South Korea), Public
Developer of genomic-based disease prevention platform
$13.3M
61/100
5th
Logo for Genprex
Genprex
2009, Austin (United States), Public
Developer of therapeutics to treat cancer at molecular level
$3.11M
56/100
6th
Logo for Bota
Bota
2019, Lafayette (United States), Series B
Developer of AI-based platform for enzyme and strain engineering
$100M
57/100
7th
Logo for Avectas
Avectas
2011, Dublin (Ireland), Series C
Provider of non-viral cell engineering technology platform for drug discovery
$33.5M
54/100
8th
Logo for Modular Genetics
Modular Genetics
2000, Woburn (United States), Series B
Developer of a proprietary, automated system for gene engineering and molecular biology
$8.9M
52/100
9th
Logo for GeneScience Pharmaceuticals
GeneScience Pharmaceuticals
1996, Changchun (China), Series B
Provides genetically engineered pharmaceuticals products
-
50/100
10th
Logo for Poseida Therapeutics
Poseida Therapeutics
2015, San Diego (United States), Acquired
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
$324M
50/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Bota's competitors? Click here to see the top ones

Bota's Investments and acquisitions

Bota has made no investments or acquisitions yet.

Reports related to Bota

Here is the latest report on Bota's sector:

News related to Bota

Media has covered Bota for a total of 3 events in the last 1 year, 3 of them have been about company updates.
•
Bota Bio and Medichem partner to advance sustainableBioSpectrum Asia•Aug 26, 2022•Bota, Medichem
•
Basf Invests In Biotech Start-up Bota BioGlobal CosmeticNews•Mar 22, 2021•BASF, Bota
•
BASF invests in biotechnology start-up Bota BioChemengonline•Mar 16, 2021•BASF, Bota
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Bota

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford